Document is current
Any future updates will be listed below
-
Authors
Patel, Milankumar
Panja, Sudipta https://orcid.org/0000-0001-5692-450X
Zaman, Lubaba A.
Yeapuri, Pravin
Bhattarai, Shaurav https://orcid.org/0000-0002-5687-0705
Gorantla, Santhi
Chang, Linda https://orcid.org/0000-0002-1267-0699
Heredia, Alonso
Walczak, Piotr https://orcid.org/0000-0002-3733-3322
Hanson, Brandon
Cohen, Samuel M. https://orcid.org/0000-0002-5047-0962
Kevadiya, Bhavesh D.
Gendelman, Howard E. https://orcid.org/0000-0002-7831-0370
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (2R01MH121402-06)
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 17 December 2024
First Online: 8 January 2025
Competing interests
: The authors declare that Dr. Howard Gendelman co-founder of Exavir Therapeutics, Inc. The biotechnology company is developing ultra-long-acting drugs. The drugs in development are not linked to those created in the current report. All other authors declare no competing interests.
